Infarct size assessment by cardiac magnetic resonance and peak troponin I after aspiration thrombectomy and intracoronary abciximab assisted primary percutaneous coronary intervention in a real-world cohort of patients with ST-segment elevation myocardial infarction: A single-center study
Conclusions In a retrospective real world cohort of patients with STEMI, no difference was found in infarct size assessed by CMR or peak TnI between the groups with and without thrombectomy. TnI-24h as well as final TIMI flow predicts infarct size. (Source: The Egyptian Heart Journal)
Source: The Egyptian Heart Journal - July 20, 2016 Category: Cardiology Source Type: research
Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program [Original Articles]
Conclusions—
In this national cohort, 18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications. (Source: Circulation: Cardiovascular Quality and Outcomes)
Source: Circulation: Cardiovascular Quality and Outcomes - July 18, 2016 Category: Cardiology Authors: Barnes, G. D., Stanislawski, M. A., Liu, W., Baron, A. E., Armstrong, E. J., Ho, P. M., Klein, A., Maddox, T. M., Nallamothu, B. K., Rumsfeld, J. S., Tsai, T. T., Bradley, S. M. Tags: Platelets, Anticoagulants, Percutaneous Coronary Intervention, Stent, Quality and Outcomes Original Articles Source Type: research
Abciximab as a bridging strategy to overcome morphine ‐prasugrel interaction in STEMI patients
ConclusionThe infusion of the GPIIb/IIIa receptor blocker abciximab allows an immediate and efficient platelet inhibition in patients with concomitant administration of the oral ADP receptor blocker prasugrel and morphine in STEMI patients. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - June 30, 2016 Category: Drugs & Pharmacology Authors: Jolanta M. Siller ‐Matula, Simon Specht, Jacek Kubica, Dimitrios Alexopoulos, Raffaele De Caterina, Eva‐Luise Hobl, Bernd Jilma, Günter Christ, Irene M. Lang Tags: Drug Interactions Source Type: research
Abciximab as a bridging strategy to overcome morphine‐prasugrel interaction in STEMI patients
ConclusionThe infusion of the GPIIb/IIIa receptor blocker abciximab allows an immediate and efficient platelet inhibition in patients with concomitant administration of the oral ADP receptor blocker prasugrel and morphine in STEMI patients. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - June 30, 2016 Category: Drugs & Pharmacology Authors: Jolanta M. Siller‐Matula, Simon Specht, Jacek Kubica, Dimitrios Alexopoulos, Raffaele De Caterina, Eva‐Luise Hobl, Bernd Jilma, Günter Christ, Irene M. Lang Tags: Drug Interactions Source Type: research
Management of coronary artery aneurysms using abciximab in children with Kawasaki disease
There are limited data regarding the possible benefits of abciximab in children with Kawasaki disease (KD), who developed serious cardiac abnormalities non-responsive to standard treatment. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - June 21, 2016 Category: Cardiology Authors: Evangelia Bachlava, Sophia Loukopoulou, Evangelos Karanasios, George Chrousos, Athanasios Michos Source Type: research
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes
ConclusionsGPIs achieve similar levels of platelet inhibition at 10 minutes and 1 hour, however abciximab maintains this benefit 24 hours after bolus dose. We did not witness an increased rate of bleeding in patients given new potent P2Y12 inhibitors and a GPI in the modern era.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - June 20, 2016 Category: Cardiology Authors: Lewis E. Holmes, Rohan Gupta, Saissan Rajendran, John Luu, John K. French, Craig P. Juergens Tags: Original Research Article Source Type: research
Delayed severe abciximab-induced thrombocytopenia: A case report
Thrombocytopenia is a possible side effect of routinely administered medical agents widely used in the management of patients with acute coronary syndromes (ACS). It is usually observed within 24 h after abciximab infusion. Differential diagnosis is challenging and the management controversial. (Source: Heart and Lung)
Source: Heart and Lung - June 19, 2016 Category: Intensive Care Authors: Łukasz Piątek, Agnieszka Janion-Sadowska, Jacek Kurzawski, Urszula Grabowska, Marianna Janion Source Type: research
Bolus Plus Infusion Remains Predominant Mode of GP IIB/IIIA Utilization: A 2015 us Hospital Purchasing Study
Platelet glycoprotein IIb/IIIa inhibitors (GPI) are utilized predominantly in patients undergoing percutaneous coronary intervention (PCI); they include the small molecules eptifibatide and tirofiban, and the monoclonal antibody abciximab. Each has bolus and infusion regimens. Clinical trials in product information have 12-24 hour minimum infusion requirements; however, bolus only or shorter infusion regimens have been explored to reduce pharmacy costs. This analysis examines 2015 eptifibatide purchasing to determine the ratio of smaller (bolus) vials to larger (infusion) vials and explore utilization patterns in contempor...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Mitchell, C Smith, R Werner Source Type: research
Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy
Background: The aim of this study was to evaluate access-site complications in patients with ST-segment elevation myocardial infarction treated with a transradial primary percutaneous coronary intervention relative to three different P2Y12 platelet inhibitors.
Patients and methods: We enrolled 334 consecutive patients (76.9% men, age: 59.4±9.1 years) treated by one of the following: clopidogrel (n=118), prasugrel (n=102), and ticagrelor (n=114). The use of the IIb/IIIa inhibitor, abciximab, was left to the operators’ discretion. The time needed to achieve patent hemostasis, compression time, and local complications wer...
Source: Coronary Artery Disease - April 27, 2016 Category: Cardiology Tags: Original Research Source Type: research
Impact of thrombus burden on procedural and mid-term outcomes after primary percutaneous coronary intervention
Objective: Angiographic thrombus burden (TB) can be assessed early and enable a decision on intervention. The aim of this study was to analyze its effect on the incidence of cardiac events after a primary percutaneous coronary intervention.
Patients and methods: We carried out a prospective study of 480 consecutive ST-segment elevation myocardial infarction patients treated by systematic primary percutaneous coronary intervention. Large TB was defined as thrombus length at least 2 vessel diameters or as solid thrombus obtained through catheter aspiration. The primary outcome measure was a composite of death, reinfarction,...
Source: Coronary Artery Disease - April 9, 2016 Category: Cardiology Tags: Original Research Source Type: research
Distinct Fibrin-{alpha}IIb{beta}3 and Fibrinogen-{alpha}IIb{beta}3 Interactions [Molecular Bases of Disease]
Fibrinogen binding to the integrin αIIbβ3 mediates platelet aggregation and spreading on fibrinogen-coated surfaces. However, in vivo αIIbβ3 activation and fibrinogen conversion to fibrin occur simultaneously, although the relative contributions of fibrinogen versus fibrin to αIIbβ3-mediated platelet functions are unknown. Here, we compared the interaction of αIIbβ3 with fibrin and fibrinogen to explore their differential effects. A microscopic bead coated with fibrinogen or monomeric fibrin produced by treating the immobilized fibrinogen with thrombin was captured by a laser beam and repeatedly brought into contac...
Source: Journal of Biological Chemistry - April 7, 2016 Category: Chemistry Authors: Litvinov, R. I., Farrell, D. H., Weisel, J. W., Bennett, J. S. Tags: Cell Biology Source Type: research
Spontaneous Bleeding from Internal Pudendal Artery associated with Abciximab after Primary Percutaneous Coronary Intervention: Successful Treatment with Percutaneous Gel-Foam Embolization.
We describe a case of spontaneous bleeding from a branch of the right internal pudendal artery that resulted in massive scrotal swelling in a patient who had underwent primary percutaneous coronary intervention with the use of abciximab concurrent with conventional anticoagulation and dual antiplatelet therapies for the treatment of acute ST-segment elevation myocardial infarction. This unusual complication was promptly identified by percutaneous peripheral arteriography and successfully treated with gel-foam embolization.
PMID: 27014357 [PubMed] (Source: Korean Circulation Journal)
Source: Korean Circulation Journal - March 27, 2016 Category: Cardiology Tags: Korean Circ J Source Type: research
Emerging Therapies in Antiphospholipid Syndrome
Abstract
Antiphospholipid syndrome (APS) is a hypercoagulable state characterized by arterial and venous thromboses and pregnancy morbidity in the presence of antiphospholipid antibodies. Although warfarin remains the main therapeutic choice in APS, there is still concern about its efficacy, safety, and patient compliance. Patients with refractory APS to conventional therapy as well as patients with non-classical manifestations of APS may have alternative treatment approaches. APS pathogenesis has been further elucidated over the past years identifying new molecules as potential new treatment targets. T...
Source: Current Rheumatology Reports - March 18, 2016 Category: Rheumatology Source Type: research
Platelet sequestration and activation during GalTKO.hCD46 pig lung perfusion by human blood is primarily mediated by GPIb, GPIIb/IIIa, and von Willebrand Factor
ConclusionsThe GPIb‐VWF and GPIIb/IIIa axes play important roles in platelet sequestration and coagulation cascade activation during GalTKO.hCD46 lung xenograft injury. GPIb blockade significantly reduces platelet activation and delays platelet sequestration in this xenolung rejection model, an effect amplified by adding αGPIIb/IIIa blockade or depletion of VWF from pig lung. (Source: Xenotransplantation)
Source: Xenotransplantation - February 29, 2016 Category: Transplant Surgery Authors: Lars Burdorf, Andrea Riner, Elana Rybak, Isabelle I. Salles, Simon F. De Meyer, Aakash Shah, Kevin J. Quinn, Donald Harris, Tianshu Zhang, Dawn Parsell, Franchesca Ali, Evan Schwartz, Elizabeth Kang, Xiangfei Cheng, Evelyn Sievert, Yuming Zhao, Gheorghe B Tags: Original Article Source Type: research
